injection of BEP 800
Phase 1Small molecule
injection of BEP 800 is one of 76 small molecule programs targeting Leukemia. It is currently in Phase 1.
2
Indications
5
Total Trials
1
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Leukemia
#DrugCompanyPhaseTrials
1Cytoxan
BBaxter Healthcare Corporation
Phase 3
Fludara
SanofiPhase 3
Vepesid
AAvyxa
Phase 3
Oncovin
Eli LillyPhase 3
Decadron
AAspen Global Incorporated
Phase 3
Leukine
SanofiPhase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Eliquis
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atrial Fibrillation1 trial
Corticosteroids Prevent the Atrial Fibrillation After Cardiac Surgery
Completed·—·Phase 1·NCT06802432·84 enrolled
Preoperative1 trial
Impact of Preoperative Single Corticosteroid Flash on Morbidity After Colorectal Resection: Monocentric Prospective Pilot Study
Terminated·—·Phase 2·NCT03437746·78 enrolled
Randomized1 trial
Corticosteroids1 trial
Benefit of a Flash Dose of Corticosteroids in Digestive Surgical Oncology: a Randomized, Double Blind, Placebo-controlled Trial
Active, not recruiting·—·Phase 3·NCT03875690·1,200 enrolled
Leukemia1 trial
Preclinical Project on the Traitment of Acute Lymphoblastique Leukemia With NVP-BEP800, an Inhibitor of the Heat Shock Protein HSP90
Unknown status·—··NCT04437420·44 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for injection of BEP 800. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details